| abstract |
REFERS TO A COMPOUND OF FORMULA WLZ WHERE W IS ARYL, CYCLOALKYL, HETEROARYL OR HETERO CYCLYL OPTIONALLY SUBSTITUTED WITH R1, R1a, R1b, R1c AND R1d, WHERE R1, R1a, R1b, R1c SONO, CND SONO AND R1B AMONG OTHERS; L IS A LINK, O, S, SO, SO2, AMONG OTHERS; Z IS A BICYCLE HETEROARYL OF FORMULA (a), (b), (c), AMONG OTHERS; WHERE R3, R3a, R3b ARE H, HALOGEN, OH, CN, NO2, AMONG OTHERS; R4 IS BICYCLE [2,2,2] OCTILO OR BICYCLE [2,2,1] HEPTILO OPTIONALLY SUBSTITUTED WITH HALOGEN, OH, CN, AMONG OTHERS, CYCLOALKYL OPTIONALLY SUBSTITUTED WITH HALOGEN, OH, CN, AMONG OTHER SUBSTITUENTS, AMONG OTHER SUBSTITUENTS. PREFERRED COMPOUNDS ARE: 3-CYCLOHEPTIL-8 - ((2,6-DICHLOROPHENOXY) METHYL) H-IMIDAZO [1,5-a] PYRIDINE, 3-CYCLOHEPTIL-8 - ((2,6-DICHLOROPHENOXY) METHYL) H- IMIDAZO [1,2-a] PYRIDINE, 3-CYCLOHEPTIL-7 - ((2,6-DICHLOROPHENOXY) METHYL) - [1,2,3] TRIAZOLO [1,5-a] PYRIDINE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF THE ENZYME 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE I, BEING USEFUL FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA, GLAUCOMA, METABOLIC SYNDROME |